| |
 |
| |
 |
The selection
and progression of appropriate clinical
candidates is a critical decision point
in our drug discovery process. Suitable
clinical candidates must display the
appropriate balance of adequate activity
against the biological target and appropriate
PK/PD and safety profiles for a once
daily oral administration. Since our
focus is on diseases of the CNS this
places an emphasis on understanding
compound actions in cellular and animal
models.
Focussing on targets within the CNS
gives us significant opportunities to
develop robust platforms for reaching
target product profiles and for the
early identification of development-limiting
issues and ways to overcome them.
A centralised drug optimization facility, which
will be available in our New Research
Centre in 2007, supporting Cancer Biology,
Neurobiology, toxicology and ADME will
allow us to develop such platforms in depth.
Our chemistry approaches to candidate
selection complete the process of knowledge
based drug design initiated in our target
and hit identification processes and
thus incorporate early use of pharmaceutical
development studies in addition to knowledge
based optimization of the compounds
against the target of interest. |
| |
| |
| |
|
|
|
|
|
